Exelixis, Inc. Announces March 8th Webcast Of Presentation At The 9th Annual Global Lehman Brothers Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that Frank Karbe, senior vice president and chief financial officer will present at the Lehman Brothers 9th Annual Global Healthcare Conference at 12:45 p.m. (PST) / 3:45 p.m. (EST) on Wednesday, March 8, 2006.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics that will potentially enhance the care and lives of patients with cancer and other serious diseases. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline covers cancer and metabolism and is comprised of the following compounds: XL119 (becatecarin), for which a multinational Phase 3 clinical trial in bile duct tumor is ongoing and which has been exclusively licensed to Helsinn Healthcare S.A.; XL784, which is being advanced as a treatment for renal disease and expected to enter Phase 2 early in 2006; XL999, an anticancer compound, currently in Phase 2 clinical trials for a variety of solid tumors; XL647, XL880, XL820, XL844 and XL184, anticancer compounds currently in Phase 1 clinical trials; and multiple compounds in preclinical development for diseases including cancer and various metabolic and cardiovascular disorders. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies including GlaxoSmithKline (GSK) and Bristol-Myers Squibb Company. Pursuant to a product development and commercialization agreement between Exelixis and GSK, GSK has the option, after completion of clinical proof-of-concept by Exelixis, to elect to develop a certain number of compounds in Exelixis' product pipeline, which may include XL784 and the cancer compounds identified in this press release (other than XL119), thus potentially triggering milestone payments and royalties from GSK and co-promotion rights by Exelixis. For more information, please visit the company's web site at www.exelixis.com.

CONTACT: Charles Butler. Director of Corporate Communications of Exelixis,Inc., +1-650-837-7277, or cbutler@exelixis.com

Web site: http://www.exelixis.com/